Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

B.H. Park, T. Hwang, T.C. Liu, D.Y. Sze, J.S. Kim, H.C. Kwon, S.Y. Oh, S.Y. Han, J. Yoon, S. Hong, A. Moon, K. Speth, C. Park, Y.J. Ahn, M. Daneshmand, B.G. Rhee, H.M. Pinedo, J. Bell, D.H. Kirn

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)533-542
JournalLancet Oncology
Volume9
Issue number6
DOIs
Publication statusPublished - 2008

Cite this

Park, B. H., Hwang, T., Liu, T. C., Sze, D. Y., Kim, J. S., Kwon, H. C., Oh, S. Y., Han, S. Y., Yoon, J., Hong, S., Moon, A., Speth, K., Park, C., Ahn, Y. J., Daneshmand, M., Rhee, B. G., Pinedo, H. M., Bell, J., & Kirn, D. H. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncology, 9(6), 533-542. https://doi.org/10.1016/S1470-2045(08)70107-4